Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11198434 | PMC |
| http://dx.doi.org/10.1016/j.jacadv.2023.100724 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Clinical Utility of Real-Time Patient Reported Outcomes in Cell Therapy Recipients.
Transplant Cell Ther
September 2025
The Dartmouth Institute for Health Policy & Clinical Practice; Geisel School of Medicine at Dartmouth, Level 5, Williamson Building, One Medical Center Drive, Lebanon, NH, 03756.
Background: The use of patient-reported outcome measures (PROMs) can improve a patient's clinical course by decreasing the incidence and severity of both physical and emotional treatment-related toxicities, uncover unmet patient needs and assist in patients' shared decision-making.
Objectives: The objective of this study was to examine the feasibility and utility of using electronically captured "real time" agenda-setting questions and PROMs at the time of the patient's clinic visit.
Study Design: We designed a prospective observational study that employed a pre-visit questionnaire (PVQ) that included agenda-setting questions and the PROMIS-29 survey, with results incorporated into a clinical decision support dashboard embedded within the patients' electronic medical record (EMR).
Patient characteristics, healthcare resource utilization and costs across treatment lines in diffuse large B-cell lymphoma - a German claims data study.
J Comp Eff Res
September 2025
Pfizer Inc, Collegeville, PA, USA.
Given the limited availability of real world diffuse large B-cell lymphoma (DLBCL) data in Germany, we assessed the baseline characteristics, treatments, clinical complications, healthcare resource utilization and costs of DLBCL across treatment lines using German claims data. In a retrospective cohort study using claims data from a German sickness fund (AOK PLUS), we identified patients with an incident DLBCL diagnosis between 2012 and 2022. Using an algorithm based on German treatment guidelines, patients were stratified into first (1L), second (2L) and third line (3L) treatment.
View Article and Find Full Text PDFPitfalls and strategies of CAR-T therapy in solid tumors and implications for chordoma treatment.
Immunotherapy
July 2025
Department of Orthopaedics, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
In recent years, CAR-T cell therapy has emerged as a promising immunotherapeutic approach, demonstrating remarkable therapeutic efficacy in hematologic malignancies such as leukemia and lymphoma. However, its effectiveness in treating solid tumors remains limited, with challenges such as low response rates, poor therapeutic persistence, and high recurrence rates. The unique and complex immune microenvironment of solid tumors, characterized by a dense extracellular matrix, an abundance of immunosuppressive cells, and cytokines, is considered a major factor impeding CAR-T cell infiltration, antitumor activity, and persistence, significantly hindering the clinical potential of this therapy.
View Article and Find Full Text PDFInnovative strategies for improving CAR-T cell therapy: A nanomedicine perspective.
Chin Med J (Engl)
July 2025
Department of Hematology, Institute of Hematology, West China Hospital, Sichuan University, 37 GuoXueXiang Street, Chengdu, Sichuan 610041, China.
Chimeric antigen receptor T (CAR-T) cells have reshaped the treatment landscape of hematological malignancies, offering a potentially curative option for patients. Despite these major milestones in the field of immuno-oncology, growing experience with CAR-T cells has also highlighted several limitations of this strategy. The production process of CAR-T cells is complex, time-consuming, and costly, thus leading to poor drug accessibility.
View Article and Find Full Text PDFRelationship between BrainAge Polygenetic Risk Score and plasma biomarkers in the A4/LEARN studies.
medRxiv
July 2025
Computational Neuroimaging Lab, BioBizkaia Health Research Institute, Barakaldo, Spain.
Background And Objectives: To examine the association between genetic predisposition to accelerated brain aging-measured with polygenic risk scores (PRS) derived from BrainAge models-and plasma biomarkers of Alzheimer's disease (AD), with attention to age and sex-specific effects.
Methods: We analyzed 1994 cognitively unimpaired participants from the A4/LEARN studies (71.5±4.